SPRING BK PHARMACEUTICALS IN's ticker is SBPH and the CUSIP is 849431101. A total of 56 filers reported holding SPRING BK PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $70,000 | -9.1% | 52,335 | 0.0% | 0.02% | -20.0% |
| Q2 2020 | $77,000 | +57.1% | 52,335 | 0.0% | 0.02% | +25.0% |
| Q1 2020 | $49,000 | -41.0% | 52,335 | 0.0% | 0.02% | -20.0% |
| Q4 2019 | $83,000 | -53.9% | 52,335 | 0.0% | 0.02% | -60.0% |
| Q3 2019 | $180,000 | -6.7% | 52,335 | 0.0% | 0.05% | -9.1% |
| Q2 2019 | $193,000 | -64.8% | 52,335 | 0.0% | 0.06% | -66.9% |
| Q1 2019 | $549,000 | +0.9% | 52,335 | 0.0% | 0.17% | -14.9% |
| Q4 2018 | $544,000 | -13.8% | 52,335 | 0.0% | 0.20% | +12.1% |
| Q3 2018 | $631,000 | +1.8% | 52,335 | 0.0% | 0.17% | -10.3% |
| Q2 2018 | $620,000 | -23.0% | 52,335 | 0.0% | 0.19% | -27.6% |
| Q1 2018 | $805,000 | +14.5% | 52,335 | 0.0% | 0.27% | +9.8% |
| Q4 2017 | $703,000 | -20.2% | 52,335 | 0.0% | 0.24% | -18.9% |
| Q3 2017 | $881,000 | +15.6% | 52,335 | -7.0% | 0.30% | +22.4% |
| Q2 2017 | $762,000 | +128.1% | 56,250 | +50.0% | 0.25% | +125.7% |
| Q1 2017 | $334,000 | – | 37,500 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 785,950 | $9,314,000 | 0.91% |
| Morse Asset Management, Inc | 177,500 | $2,103,000 | 0.58% |
| PARSONS CAPITAL MANAGEMENT INC/RI | 281,213 | $3,332,000 | 0.38% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 73,000 | $860,000 | 0.33% |
| TIEDEMANN ADVISORS, LLC | 412,049 | $4,883,000 | 0.31% |
| Private Capital Advisors, Inc. | 52,335 | $620,000 | 0.19% |
| SECTORAL ASSET MANAGEMENT INC | 131,656 | $1,560,000 | 0.17% |
| Lee Financial Co | 18,750 | $222,000 | 0.05% |
| Baker Brothers Advisors | 373,144 | $4,422,000 | 0.03% |
| Alyeska Investment Group, L.P. | 200,000 | $2,370,000 | 0.02% |